Gilead Sciences, Inc. $GILD Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,280,740 shares of the biopharmaceutical company’s stock after selling 72,218 shares during the period. Gilead Sciences comprises about 1.0% of Skandinaviska Enskilda Banken AB publ’s holdings, making the stock its 14th largest position. Skandinaviska Enskilda Banken AB publ owned 0.18% of Gilead Sciences worth $253,196,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Csenge Advisory Group boosted its holdings in shares of Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after acquiring an additional 16,288 shares during the period. Cookson Peirce & Co. Inc. increased its holdings in shares of Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after acquiring an additional 7,168 shares during the period. Railway Pension Investments Ltd raised its position in Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares during the last quarter. TriaGen Wealth Management LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth $1,274,000. Finally, iA Global Asset Management Inc. boosted its stake in Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after purchasing an additional 23,046 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the sale, the chief executive officer owned 613,912 shares in the company, valued at $92,086,800. This represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 288,891 shares of company stock worth $40,303,946 over the last three months. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on GILD. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Rothschild & Co Redburn boosted their price target on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. The Goldman Sachs Group lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Finally, Mizuho upped their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $152.50.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $154.98 on Tuesday. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a 50 day simple moving average of $130.94 and a 200-day simple moving average of $122.68. The company has a market cap of $192.28 billion, a price-to-earnings ratio of 22.89, a price-to-earnings-growth ratio of 2.06 and a beta of 0.36. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. The ex-dividend date is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.